Natera (NASDAQ:NTRA) CFO Sells $9,016,424.50 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 37,175 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50. Following the completion of the sale, the chief financial officer owned 64,123 shares of the company’s stock, valued at approximately $15,552,392.42. This trade represents a 36.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,621,553.52.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The shares were sold at an average price of $190.64, for a total transaction of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The shares were sold at an average price of $191.16, for a total value of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $192.32, for a total value of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $196.77, for a total value of $148,561.35.

Natera Price Performance

Shares of Natera stock opened at $241.58 on Friday. The firm has a fifty day moving average price of $234.18 and a two-hundred day moving average price of $191.40. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The company has a market cap of $33.42 billion, a PE ratio of -105.49 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company’s revenue was up 34.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. Analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. BNP Paribas Exane upgraded shares of Natera to a “hold” rating and set a $172.00 price target on the stock in a research note on Monday, October 27th. Morgan Stanley raised their price objective on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Citigroup started coverage on shares of Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Thursday. Finally, Evercore ISI raised their price target on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $245.50.

Hedge Funds Weigh In On Natera

Several institutional investors have recently added to or reduced their stakes in NTRA. Vanguard Group Inc. increased its holdings in shares of Natera by 2.3% during the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after buying an additional 282,826 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after purchasing an additional 1,003,129 shares in the last quarter. State Street Corp raised its position in Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the last quarter. Franklin Resources Inc. boosted its stake in Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Natera by 7.0% in the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after purchasing an additional 166,768 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.